Table 1 Direct (nalmefene versus placebo and naltrexone versus placebo) and indirect (nalmefene versus naltrexone) meta-analyses concerning change from baseline in quantity of drinking
From: Evaluation in alcohol use disorders – insights from the nalmefene experience
Studies | Abstinence criterion | Consumption criterion | Soyka et al. analysis | Analysis of complete data |
|---|---|---|---|---|
Quantity of drinking | Quantity of drinking | |||
SMD [95 % CI] | SMD [95 % CI] | |||
CPH-101-0801a | No more than 14 days | At least 18 heavy drinking days in the last 12 weeks | −0.48 [−0.87; −0.09] | −0.21 [−0.46; 0.03] |
ESENSE 1a [3] | No more than 14 days | At least 40 g alcohol/day for men and 20 g alcohol/day for women and ≥6 heavy drinking days in the last 4 weeks | −0.46 [−0.74; −0.17] | −0.35 [−0.56; −0.14] |
ESENSE 2a [2] | No more than 14 days | At least 40 g alcohol/day for men and 20 g alcohol/day for women and ≥6 heavy drinking days in the last 4 weeks | −0.25 [−0.52; 0.02] | −0.15 [−0.34; 0.04] |
SENSEa [4] | No more than 14 days | >6 heavy drinking days in the last 4 weeks | −0.36 [−0.76; 0.03] | −0.12 [−0.34; 0.1] |
Nalmefene versus placebo, direct comparison, fixed-effect model | −0.37 [−0.53; −0.21] | −0.21 [−0.31; −0.10] | ||
Anton (1999) [45] | At least 5 days | 5 or more drinks per day in the last 30 days | −0.35 [−0.69; −0.01] | −0.35 [−0.69; −0.01] |
Balldin (2003) [46] | No more than 14 days | At least 20 heavy drinking days in the last 60 days | 0.01 [−0.35; 0.37] | 0.01 [−0.35; 0.37] |
Anton (2005) [47] | At least 5 days | Average consumption of at least 5 standard drinks per day for men and 4 for women in the past 90 days | −0.18 [−0.49; 0.13] | −0.18 [−0.49; 0.13] |
Kranzler (2000) [48] | At least 3 days and no longer than 28 days | Not specific | 0.02 [−0.33; 0.37] | 0.02 [−0.33; 0.37] |
O’Malley (2008) [49] | At least 4 days and no more than 30 days | More than 14 drinks (women) or 21 drinks (men) per week and at least 2 heavy drinking days during a 30-day period within the 90 days prior to baseline. | 0.08 [−0.39; 0.55] | 0.08 [−0.39; 0.55] |
Naltrexone versus placebo, direct comparison, fixed-effect model | −0.11 [−0.27; 0.05] | −0.11 [−0.27; 0.05] | ||
Nalmefene versus Naltrexone, indirect comparison, fixed-effect model | −0.26 [−0.04; −0.49] | −0.10 [−0.29; 0.10] | ||
Heterogeneity in the network | I2 = 0 %. Q = 5.9. p = 0.65 | I2 = 0 %. Q = 6.4. p = 0.50 | ||